Home / Market News / $MDT
benzinga Corporate Catalyst Impact 65/100 ● positive

Medtronic Receives FDA Clearance, CE Mark For Its Affera Prism-2 Mapping Software, Also Receives CE Mark For PulseSelect ProxBox Adapter

Sep 30, 2026, 1:04 PM UTC · Primary ticker $MDT

Medtronic announced regulatory clearances for its Affera Prism-2 Mapping Software (FDA and CE Mark) and CE Mark for the PulseSelect ProxBox Adapter. These approvals enhance the company's cardiac ablation portfolio by expanding integrated mapping and tissue-proximity capabilities, potentially boosting product adoption and market share in the electrophysiology space.

Medtronic has secured significant regulatory milestones with FDA clearance and CE Mark for its Affera Prism-2 Mapping Software, alongside a CE Mark for the PulseSelect ProxBox Adapter. This matters because these approvals allow Medtronic to market and sell these enhanced cardiac ablation tools in the U.S. and Europe, expanding their integrated mapping and tissue-proximity capabilities. This development primarily affects Medtronic, strengthening its competitive position in the electrophysiology market. In the short term, this could lead to increased sales and market penetration for these specific products. Long-term, it reinforces Medtronic's innovation pipeline and ability to deliver advanced solutions, potentially driving sustained revenue growth. The key opportunity for traders is the potential for increased adoption of Medtronic's cardiac ablation platforms, leading to a positive impact on the company's stock performance.

$MDT positive Regulatory approvals for key products
$JNJ neutral Competitor in medical devices, potential indirect impact
$ABT neutral Competitor in medical devices, potential indirect impact
Source: benzinga
Join the waitlist for full signal validation →

Not financial advice. AI-generated analysis for informational purposes only.